We are live on ! Find out more
CASI

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

31 hedge funds and large institutions have $2.59M invested in CASI Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

7% more funds holding

Funds holding: 29 → 31 (+2)

32% less capital invested

Capital invested by funds: $3.84M → $2.59M (-$1.24M)

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

Holders
31
Holders Change
+2
Holders Change %
+6.9%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
6
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CWM
Concert Wealth Management
California
+$60K
2
VKH
Virtu KCG Holdings
New York
+$28.7K
3
Millennium Management
Millennium Management
New York
+$24.8K
4
Renaissance Technologies
Renaissance Technologies
New York
+$9.22K
5
UBS Group
UBS Group
Switzerland
+$7.27K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$58.5K
2
MC
Moors & Cabot
Massachusetts
-$8.29K
3
WSCM
Wellington Shields Capital Management
New York
-$2.65K
4
BFA
BlackRock Fund Advisors
California
-$1.34K
5
TRCT
Tower Research Capital (TRC)
New York
-$1K

CASI Hedge Fund Activity: Q3 2015 in Review

31 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q3 2015, worth a combined $2.59M — down 32% from $3.84M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CASI positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 6 trimmed.

The largest buyer was Concert Wealth Management, opening a new position worth an estimated $60K. The largest seller was Sabby Management, cutting an estimated $58.5K.

  • 31 institutional investors held CASI Pharmaceuticals (CASI) as of Q3 2015, up from 29 in Q2 2015.
  • Funds reported $2.59M of CASI Pharmaceuticals stock for Q3 2015, down 32% quarter-over-quarter.
  • 4 funds opened new CASI Pharmaceuticals positions in Q3 2015 and 2 closed out, a net change of +2 holders.
  • The largest CASI Pharmaceuticals buyer in Q3 2015 was Concert Wealth Management, an estimated $60K added.
  • The largest CASI Pharmaceuticals seller in Q3 2015 was Sabby Management, an estimated $58.5K sold.

Based on aggregated 13F filings for Q3 2015.